Omotola Olasupo and Colleagues Present Comparative Safety of Hemophilia Therapies in Canada
RPTH Journal shared on LinkedIn:
”Comparative safety of hemophilia therapies in Canada
Real-world comparative safety data for hemophilia therapies remain limited.
This study leverages national registry data to better understand adverse drug reactions across commonly used treatments using Canadian registry data over 5 years
- Allergic reactions were the most frequently reported adverse drug reactions
- A higher number of reported events was observed with emicizumab, although novelty bias cannot be excluded
- No inhibitor development was reported with emicizumab or bypassing agents
These findings provide important real-world insights into the relative safety of therapies used in hemophilia A and B, while highlighting the need for continued pharmacovigilance as treatment landscapes evolve.”
Read the full article here.
Article: Comparative safety of drug therapies used in hemophilia A and B in Canada: a multi-center, retrospective study
Authors: Omotola Olasupo, Emma Iserman, Arun Keepanasseril, Quazi Ibrahim, Zainab Salim Ali Al-Housni, Federico Germini, Jean-Eric Tarride, Lawrence Mbuagbaw, Shannon Jackson, Ingrid Blydt-Hansen, Michelle Bech, Celina Woo, Mark Belletrutti, Alfonso Iorio, Davide Matino: the Association of Hemophilia Clinic Directors of Canada (AHCDC)
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 11, 2026, 14:45Jorge Mascaro: The Growing Impact of the UK Aortic Society on Aortic Disease Care
-
Sep 11, 2026, 14:31Hany Ibrahim: Lp(a) Lowering Meets a Critical Test in the Lp(a)HORIZON Trial
-
Sep 11, 2026, 13:35How Non-Factor Therapies Are Changing Hemophilia Care – Seminars in Thrombosis and Hemostasis
-
Sep 11, 2026, 13:21Emmanuel J Favaloro: Rethinking Quality Control in VWD Testing
-
Sep 11, 2026, 13:10Tessa Youngner: New Free E-Course Introduces Comprehensive SCD Care
-
Sep 11, 2026, 12:55Identifying Key Research Priorities for VTE and Stroke – International Journal of Stroke
-
Sep 11, 2026, 12:43Helping Hematology Employers Reach Qualified Job Seekers – ASH
-
Sep 11, 2026, 12:22The First New Treatment for Essential Thrombocythemia in Nearly 30 Years
-
Sep 11, 2026, 12:20When Thrombosis Affects the Kidneys – World Thrombosis Day